Late-Breaking Comparative Study in MAFLD/Obesity at BIO24:
BMD-003 Outshines GLP1 in Metabolic Health
Lead program: BMD-003
💡 Significantly boosts insulin sensitivity;
💡 Effectively cuts down on hepatic steatosis and lipid build-up and
💡 Specifically targets white adipose tissue while minimizing food intake.
Comparative Study Outcomes Versus
Commercially Available GLP1 Programs:
📊 25% reduction in body weight, revealing materially less impact on food intake than commercially available GLP1 products that severely influence food intake.
📊 Weight loss via fat mass reduction while preserving lean mass, offering a specialized approach to tackling obesity—differing from competitors that primarily influence food intake.
📊 Stimulates a modest reduction in food intake, reinforcing that BMD-003's efficiency in weight loss is more than just appetite suppression, a common effect observed in GLP1 treatments.
📊 Differentiation in Fat vs. Lean Mass Reduction: BMD-003 stands alone for its selective reduction in fat mass, not at the expense of lean mass. This underpins maintaining muscle integrity and metabolic health throughout weight loss.
BMD-003 Further Highlights:
📊 Efficiency revered abdominal lipid profiles induced by insulin resistance, such as high LDA, high triglyceride, and high cholesterol levels;
📊 Normalized increased levels of ALT and AST activities that are markers of liver damage
🧬 BMD-003 is a novel, targeted approach to treating metabolic disorders by preserving lean muscle mass while effectively reducing fat mass. It is an SC-formulated miRNA inhibitor designed as a patient-friendly approach to combating metabolic dysfunction-associated fatty liver disease (MAFLD) and obesity.
We are pleased that this program will be partnered with scientists who share our vision for IV-formulated and SC-formulated RNA therapeutics to combat systemic targets. #INHBEgene. #MetabolicDysfunction, #MAFLD, #ObesityResearch, #MASH, ONO PHARMA USA, ONO PHARMACEUTICAL CO., LTD., AstraZeneca, Pfizer, #pfizercolleague, Stephane Caron, Danna Breen, Steven Terra, Jeff Pfefferkorn, Julie Post, Søren Tullin, Hendrik Knoetgen, Dicerna Pharmaceuticals, Inc., Novo Nordisk, Mads Krogsgaard Thomsen, Novo Holdings, Kasim Kutay, AbbVie, GSK, Bayer, Bristol Myers Squibb, Biogen, Sanofi, PJT Partners, ClearView Healthcare Partners, Roche, Branden JH (jin-hyeob) RYU, IL-SANG YOON, Akira Morikawa, Endpoints News, STAT, State Street, Brendan Nagle, Jerry Iwata, Wells Fargo Corporate & Investment Banking, Jeffrey Leerink. DM: davidoxley@biorchestra.com
